WO2024254519A3 - Compositions and methods for the modification of human genes expressed by liver cells - Google Patents

Compositions and methods for the modification of human genes expressed by liver cells Download PDF

Info

Publication number
WO2024254519A3
WO2024254519A3 PCT/US2024/033100 US2024033100W WO2024254519A3 WO 2024254519 A3 WO2024254519 A3 WO 2024254519A3 US 2024033100 W US2024033100 W US 2024033100W WO 2024254519 A3 WO2024254519 A3 WO 2024254519A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
modification
liver cells
human genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033100
Other languages
French (fr)
Other versions
WO2024254519A2 (en
Inventor
Sean Chen
Lucas Benjamin HARRINGTON
William Douglass WRIGHT
Aaron DELOUGHERY
Wiputra Jaya HARTONO
Benjamin Julius RAUCH
Stepan TYMOSHENKO
Lauren Kelli UYESAKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mammoth Biosciences Inc
Original Assignee
Mammoth Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mammoth Biosciences Inc filed Critical Mammoth Biosciences Inc
Publication of WO2024254519A2 publication Critical patent/WO2024254519A2/en
Publication of WO2024254519A3 publication Critical patent/WO2024254519A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are compositions, systems, and methods comprising effector proteins, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the editing and/or engineering of nucleic acids.
PCT/US2024/033100 2023-06-08 2024-06-07 Compositions and methods for the modification of human genes expressed by liver cells Ceased WO2024254519A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363507030P 2023-06-08 2023-06-08
US63/507,030 2023-06-08
US202363586743P 2023-09-29 2023-09-29
US63/586,743 2023-09-29
US202363603618P 2023-11-28 2023-11-28
US63/603,618 2023-11-28

Publications (2)

Publication Number Publication Date
WO2024254519A2 WO2024254519A2 (en) 2024-12-12
WO2024254519A3 true WO2024254519A3 (en) 2025-04-17

Family

ID=93796423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033100 Ceased WO2024254519A2 (en) 2023-06-08 2024-06-07 Compositions and methods for the modification of human genes expressed by liver cells

Country Status (1)

Country Link
WO (1) WO2024254519A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190247517A1 (en) * 2017-10-17 2019-08-15 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing for hemophilia a
US20200270618A1 (en) * 2018-10-18 2020-08-27 Intellia Therapeutics, Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
WO2023039378A1 (en) * 2021-09-08 2023-03-16 Metagenomi, Inc. Class ii, type v crispr systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190247517A1 (en) * 2017-10-17 2019-08-15 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing for hemophilia a
US20200270618A1 (en) * 2018-10-18 2020-08-27 Intellia Therapeutics, Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
WO2023039378A1 (en) * 2021-09-08 2023-03-16 Metagenomi, Inc. Class ii, type v crispr systems

Also Published As

Publication number Publication date
WO2024254519A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2023102329A3 (en) Effector proteins and uses thereof
WO2022140577A3 (en) Compositions and methods for epigenetic editing
WO2017027423A9 (en) Engineered crispr-cas9 compositions and methods of use
WO2021247570A3 (en) Compositions and methods for gene editing
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
WO2020123887A3 (en) Novel crispr-cas systems for genome editing
WO2018191715A3 (en) Polypeptides with type v crispr activity and uses thereof
WO2019089884A3 (en) Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
WO2023023285A3 (en) Methods and compositions relating to covalently closed nucleic acids
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
WO2022051020A3 (en) Systems, methods, and compositions for rna-guided rna-targeting crispr effectors
WO2017070632A3 (en) Nucleobase editors and uses thereof
EP1829892A3 (en) Staphylococcus aureus proteins and nucleic acids
WO2023235818A3 (en) Engineered class 2 type v crispr systems
WO2023250183A3 (en) Compositions and methods for epigenetic editing
WO2023141590A3 (en) Effector proteins and methods of use
WO2024148313A3 (en) Genome editing compositions and methods of use
WO2023220649A3 (en) Effector protein compositions and methods of use thereof
WO2024138202A3 (en) Effector proteins, compositions, systems and methods of use thereof
WO2024254519A3 (en) Compositions and methods for the modification of human genes expressed by liver cells
WO2024108016A3 (en) Methods for quantitation of nucleic acid targets
WO2023220654A3 (en) Effector protein compositions and methods of use thereof
WO2024192211A3 (en) Effector proteins and uses thereof
WO2024006824A3 (en) Effector proteins, compositions, systems and methods of use thereof
WO2023220570A9 (en) Engineered cas-phi proteins and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820175

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE